Filtered By:
Drug: Rituxan

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 5023 results found since Jan 2013.

'trimming the diagnosis
We report a 52-year old female who initially presented with episodes of vertigo, headache and diplopia. Vestibular migraine or Meniere's disease was diagnosed. Two-years later she reported sensory symptoms in her upper limbs. Normal investigations led to a functional diagnosis being considered. However she worsened with an acute-onset sensorineural hearing loss and diplopia. Examination revealed evidence of brainstem signs and ataxia. MRI showed an enhancing right dorsal pontine lesion, CSF was normal. She was diagnosed with primary CNS angiitis and managed with steroids and mycophenolate. Improvement was noted but on tape...
Source: Journal of Neurology, Neurosurgery and Psychiatry - November 14, 2016 Category: Neurosurgery Authors: Ahmed, W., Carroll, L. S., Coe, J. S., Rashid, W., Eva, B. Tags: Immunology (including allergy), Drugs: CNS (not psychiatric), Headache (including migraine), Pain (neurology), Ophthalmology, Vascularitis, Ear, nose and throat/otolaryngology ABN Annual Meeting, 17-19 May 2016, The Brighton Centre, Brighton Source Type: research

The Cerebrospinal Fluid in Multiple Sclerosis
Conclusions OCB are important biomarkers that can support MRI diagnostics and help to avoid false-positive MS diagnoses. Therefore, the revised McDonalds criteria have increased the importance of the OCB. New biomarkers such as AQP4 have now established themselves in clinical practice, and others such as Anti-MOG and NfL are about to enter clinical routine. An important focus in the search for new biomarkers is the monitoring of therapy efficacy and the prediction of severe side effects. Many other CSF molecules such as CHI3L1, IL-6, or CXCL13 show potential as markers for clinical practice, but further research is nee...
Source: Frontiers in Immunology - April 11, 2019 Category: Allergy & Immunology Source Type: research

A Systematic Review on Predisposition to Lymphoid (B and T cell) Neoplasias in Patients With Primary Immunodeficiencies and Immune Dysregulatory Disorders (Inborn Errors of Immunity)
Conclusions Though this is not a comprehensive summary of malignancies in PIDDs, or even lymphoproliferative disease in this area, this review summarizes the Medline-indexed published reports of B and T lymphomas in patients with PIDDs. This report highlights the diversity of malignant lymphoproliferative disorders in setting of PIDDs, and its associated challenges of diagnosis and treatment. The pathological classification and nomenclature for the lymphoid malignancies with variably reported and postulated underlying mechanisms were inconsistent and inadequate for many of these published reports. A wide range of treatmen...
Source: Frontiers in Immunology - April 15, 2019 Category: Allergy & Immunology Source Type: research

Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome
CONCLUSIONS: This updated review strengthened the evidence that immunosuppressive therapy is probably superior to non-immunosuppressive therapy in inducing remission and reducing the number of patients that progress to ESKD. However, these benefits need to be balanced against the side effects of immunosuppressive drugs. The number of included studies with high-quality design was relatively small and most studies did not have adequate follow-up. Clinicians should inform their patients of the lack of high-quality evidence. An alkylating agent (cyclophosphamide or chlorambucil) combined with a corticosteroid regimen had short...
Source: Cochrane Database of Systematic Reviews - November 15, 2021 Category: General Medicine Authors: Thilo C von Groote Gabrielle Williams Eric H Au Yizhi Chen Anna T Mathew Elisabeth M Hodson David J Tunnicliffe Source Type: research

Interventions for focal segmental glomerulosclerosis in adults
CONCLUSIONS: No RCTs, which evaluated corticosteroids, were identified although the KDIGO guidelines recommend corticosteroids as the first treatment for adults with FSGS. The studies identified included participants with steroid-resistant FSGS. Treatment with cyclosporin for at least six months was more likely to achieve complete remission of proteinuria compared with other treatments but there was considerable imprecision due to few studies and small participant numbers. In future studies of existing or new interventions, the investigators must clearly define the populations included in the study to provide appropriate r...
Source: Cochrane Database of Systematic Reviews - February 28, 2022 Category: General Medicine Authors: Elisabeth M Hodson Aditi Sinha Tess E Cooper Source Type: research

Interventions for minimal change disease in adults with nephrotic syndrome
CONCLUSIONS: This updated review has identified evidence for the efficacy and adverse effects of CNIs and EC-MPS with or without reduced-dose prednisolone compared with prednisolone alone for the induction of remission in adults with MCD and nephrotic syndrome with some reductions in steroid-associated adverse events. RCT data on the efficacy and adverse effects of rituximab in adults with MCD are awaited. Further, adequately powered RCTs are required to determine the relative efficacies of CNIs and EC-MPS and to evaluate these medications in patients with relapsing or steroid-resistant disease.PMID:35230699 | DOI:10.1002/...
Source: Cochrane Database of Systematic Reviews - March 1, 2022 Category: General Medicine Authors: Karolis Azukaitis Suetonia C Palmer Giovanni Fm Strippoli Elisabeth M Hodson Source Type: research

Interventions for focal segmental glomerulosclerosis in adults
CONCLUSIONS: No RCTs, which evaluated corticosteroids, were identified although the KDIGO guidelines recommend corticosteroids as the first treatment for adults with FSGS. The studies identified included participants with steroid-resistant FSGS. Treatment with cyclosporin for at least six months was more likely to achieve complete remission of proteinuria compared with other treatments but there was considerable imprecision due to few studies and small participant numbers. In future studies of existing or new interventions, the investigators must clearly define the populations included in the study to provide appropriate r...
Source: Cochrane Database of Systematic Reviews - February 28, 2022 Category: General Medicine Authors: Elisabeth M Hodson Aditi Sinha Tess E Cooper Source Type: research

Biologic therapies and bone loss in rheumatoid arthritis
ConclusionTreatment with biologic drugs is associated with the decrease in bone loss. Studies with anti-TNF blocking agents show preservation or increase in spine and hip BMD and also a better profile of bone markers. Most of these studies were performed with infliximab. Only three epidemiological studies analyzed the effect on fractures after anti-TNF blocking agent ’s treatment. IL-6 blocking agents also showed improvement in localized bone loss not seen with anti-TNF agents. There are a few studies with rituximab and abatacept. Although several studies reported favorable actions of biologic therapies on bone protectio...
Source: Osteoporosis International - January 27, 2017 Category: Orthopaedics Source Type: research

Hematological Side Effects of Immune Checkpoint Inhibitors: The Example of Immune-Related Thrombocytopenia
Conclusion Hem-irAEs are potentially life-threatening complications of ICIs that require a high level of clinical suspicion. Ir-TCP is amongst the most frequently reported hem-irAEs. Due to its low incidence and the lack of specific diagnostic criteria, ir-TCP may be underdiagnosed and possibly underreported. The diagnosis is based on exclusion of other causes of TCP together with clinical features that suggest an immune event such as the refractoriness to platelet transfusions and response to corticosteroids. During clinical development, a systematic analysis of ir-TCP cases at clinical study and program level is of outm...
Source: Frontiers in Pharmacology - April 25, 2019 Category: Drugs & Pharmacology Source Type: research

Vaccination against SARS-CoV-2 in patients with multiple sclerosis
CONCLUSION: The data available make it possible to recommend mRNA vaccines against SARS-CoV-2 in patients with multiple sclerosis. In patients on fingolimod, cladribine, alemtuzumab, ocrelizumab and rituximab, vaccination prior to the initiation of medication administration would be recommendable whenever possible.PMID:33764494 | DOI:10.33588/rn.7207.2021097
Source: Revista de Neurologia - March 25, 2021 Category: Neurology Authors: L Costa Frossard-Fran ça J M Garc ía-Domínguez I Moreno-Torres J Fort ún L M Villar V Meca-Lallana Source Type: research